Advanced Filters
noise

non-small-cell-lung-cancer Clinical Trials

A listing of non-small-cell-lung-cancer medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

Found 1,203 clinical trials
Y Yongchang Zhang, MD

A Real-World Study of Atezolizumab in Combination With Platinum-Based Doublet Chemotherapy as Neoadjuvant Therapy for Resectable Stage II-IIIB NSCLC

This is a descriptive observational study, in which data are collected in an epidemiological fashion and prospective. This study does not intend to intervene the current medical practice of the recruited patients.

18 years of age All Phase N/A
W Wenhua Liang, M.D

A Study to Explore the Role and Impact of Wearable Smart Devices in Perioperative NSCLC Patients

The trial was designed as a single-center non-interventional prospective observational study to explore the role and impact of wearable smart devices in perioperative NSCLC patients.

18 years of age All Phase N/A
Y Yongchang Zhang, MD

A Retrospective Study: Evaluation of the Efficacy of Immunotherapy With Rare Mutations in Non-small Cell Lung Cancer

In advanced non-small cell lung cancer, there will be some rare mutations, such as ALK, KRAS, etc. The efficacy of these immunotherapies on these different rare mutations has not been reported. Therefore, we conducted this retrospective clinical study to explore the efficacy of immunotherapy for different rare mutations.

18 - 75 years of age All Phase N/A
Y Yongchang Zhang, MD

Pembrolizumab Combined With Double Platinum Based Chemotherapy for Potentially Resectable NSCLC

This study aims to explore the efficacy and safety of Pembrolizumab Combined With Double Platinum-Based Chemotherapy for Potentially Resectable Non-driver Gene Mutation Non-small Cell Lung Cancer

18 years of age All Phase N/A

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

This is an open label, prospective, multicenter, non-comparative study to assess the safety and effectiveness of Tabrecta® (Capmatinib) in real world setting. Also, this study is to fulfill the regulatory requirements as part of the RMP (Risk Management Plan) for Tabrecta® (Capmatinib), as requested by Korea Health Authority, MFDS (Ministry …

18 years of age All Phase N/A
W Wenxiang Wang

Multiomics Tumor Evolution Model of NSCLC

The purpose of this study is to determine the evolutionary mechanism of early-stage non-small cell lung cancer and establish an accurate prognostic model and a recurrence monitoring system by multiomics analysis, which can be helpful for the individual and whole management of lung cancer patients and improve the overall prognosis.

18 years of age All Phase N/A
C Clemens Aigner, Prof. Dr.

Efficacy of Torque Teno Virus as a Biomarker for Predicting Treatment Response of Immune Checkpoint Inhibitor Therapy and Postoperative Outcome in NSCLC Patients

First discovered in 1997 the torque teno virus (TTV) can be found in the vast majority of the human population throughout their lifetime. The TTV levels correlate with infectious diseases and organ rejection and are therefore currently being investigated as a tool to optimize the management of patients after solid …

18 years of age All Phase N/A
Y Yongchang Zhang, MD

ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.

18 years of age All Phase N/A
z ziming Li

A Study of Molecular Residual, Dynamic Monitoring and Recurrence of Stage III Driver Mutated NSCLC

The goal of this prospective, observational study is to explore the value of dynamic monitoring of minimal residual lesions in driver mutated stage III NSCLC for disease recurrence and prognosis assessment. The main question it aims to answer is: Whether MRD(Minimal residual disease) status can predict recurrence events in stage …

18 years of age All Phase N/A
Z Zhijie Wang, MD

Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer

Lung cancer is one of the diseases with the highest global incidence and mortality. Studies have confirmed that liquid biopsy markers such as minimal residual disease (MRD) detection in solid tumors, circulating tumor DNA (ctDNA), and T-cell receptor (TCR) have roles in monitoring disease status, prognostic evaluation, recurrence prediction, and …

18 years of age All Phase N/A

Simplify language using AI